XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash flows used in operating activities:              
Net loss $ (1,728) $ (1,087) $ 526 $ (3,150) $ (4,654) $ (11,771)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         273 778  
Amortization of deferred financing costs and debt discount         428 354  
In process research and development acquired from NanoTx Therapeutics         781    
Noncash lease expenses         2 22  
Change in fair value of warrants 81   561   (2,342) 69  
Share-based compensation expense         149 106  
Loss on sale of business           6,508  
Allocation of issuance costs associated with warrants     1,233     1,233  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Accounts receivable         1,169 (4,851)  
Inventories           274  
Other current assets         516 252  
Other assets         54 298  
Accounts payable and accrued expenses         (1,586) (297)  
Deferred revenues           29  
Other long-term liabilities           54  
Net cash used in operating activities         (5,210) (6,942)  
Cash flows provided by (used in) investing activities:              
Purchases of property and equipment         (37) (8)  
In process research and development acquired from NanoTx Therapeutics         (400)    
Proceeds from sale of business           5,637  
Net cash provided by (used in) investing activities         (437) 5,629  
Cash flows used in financing activities:              
Principal payments of long-term obligations         (5,307) (3,490)  
Payment of financing lease liability (42)   (1)   (93) (75)  
Proceeds from exercise of warrants         1,081 491  
Proceeds from sale of common stock, net           15,964  
Net cash provided by (used in) financing activities         (4,319) 12,890  
Effect of exchange rate changes on cash and cash equivalents           (4)  
Net increase (decrease) in cash and cash equivalents         (9,966) 11,573  
Cash, cash equivalents, and restricted cash at beginning of period   $ 17,592   $ 5,301 17,592 5,301 $ 5,301
Cash, cash equivalents, and restricted cash at end of period $ 7,626   $ 16,874   7,626 16,874 $ 17,592
Cash paid during period for:              
Interest         470 1,071  
Supplemental schedule of non-cash investing and financing activities:              
Issuance costs paid in common stock         463    
Common stock issued in payment for in process research and development         381    
Offering cost paid in warrants           213  
Unpaid offering costs         $ 12 $ 403